

FOI REF: 22/083

Tel: 0300 131 4500

Website: www.esht.nhs.uk

21st February 2022

FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:

Please see below for the number of patients treated during the period November 2021 to January 2022 inclusive:

• Avelumab + Axitinib	5
• Axinitib	0
• Cabozantinib	0
• Everolimus	0
• Lenvantinib + Everolimus	0
• Nivolumab	4
• Nivolumab + Ipilimumab	3
• Pazopanib	0
• Pembrolizumab + Axitinib	0
• Pembrolizumab monotherapy	0
• Sunitinib	0
• Temsirolimus	0
• Tivozanib	0
• Other active systemic anti-cancer therapy	0

Cont.../

Q2. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

Please see the table below for the number of patients that have undergone full or partial nephrectomy for the period November 2021 to January 2022 inclusive:

Number of Patients	Number of Admissions	Procedure Code	Procedure Description
3	3	M101	Endoscopic Extirpation of Lesion of Kidney Nec
8	8	M021	Nephrectomy And Excision of Perirenal Tissue
2	2	M022	Nephroureterectomy Nec
6	6	M039	Unspecified Partial Excision of Kidney

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, please write to the Freedom of Information Department (esh-tr.foi@nhs.net), quoting the above reference.

Yours sincerely

Linda Thornhill (Mrs)
Corporate Governance Manager
esh-tr.foi@nhs.net